The SOTA Section Most Manufacturers Get Wrong

Written by HATEM RABEH, MD, MSc Ing

Your Clinical Evaluation Expert And Partner

in
S

This confusion is surprisingly common. When manufacturers prepare the State of the Art (SOTA) section, they often focus on what devices exist instead of what technological approaches exist to solve the clinical problem. They list products when they should be analyzing principles.

The MDR requires you to demonstrate knowledge of the current state of the art, including alternative solutions. But what regulators actually want to see is whether you understand the landscape of technological approaches and can justify why your chosen approach is appropriate.

Let me show you what this actually means in practice.

What Alternative Technology Assessment Really Means

Alternative technology assessment is not a market survey. It is not a competitor analysis. It is not a list of similar devices with CE marks.

It is a systematic evaluation of the different technological principles that could address the same clinical condition or achieve the same therapeutic goal as your device.

Consider a Class IIb wound dressing with antimicrobial properties. The clinical problem is preventing infection in chronic wounds. What are the alternative technological approaches?

You might have silver-based antimicrobial systems, iodine-based systems, honey-based systems, polyhexanide systems, or antimicrobial peptides. You might also have physical approaches like negative pressure wound therapy or oxygen therapy systems.

Each of these represents a different technological principle. Some are chemical, some are biological, some are physical. That is the level of analysis required.

Why This Matters for Your Clinical Evaluation

The alternative technology section serves a specific regulatory function. It demonstrates that you have considered whether other approaches might be safer or more effective for the intended purpose.

This directly supports your benefit-risk determination under MDR Article 61(1) and Annex I. If you have not genuinely assessed alternatives, you cannot claim that your device provides an acceptable benefit-risk ratio.

I see manufacturers write things like: “There are several devices on the market similar to ours, but our device has unique features.” Then they list features without explaining why those features matter clinically or how they compare to alternative technological approaches.

This tells the reviewer nothing about whether you understand the state of the art. It tells them you know how to search a regulatory database.

What Happens During Review

When a Notified Body reviewer reads your alternative technology section, they are asking specific questions:

Does the manufacturer understand what other technological solutions exist? Have they considered fundamentally different approaches, or only variations of their own approach? Can they explain the advantages and limitations of each approach based on clinical evidence?

If your section reads like a marketing comparison, these questions remain unanswered. The reviewer then has to question whether your benefit-risk analysis is based on genuine understanding or commercial positioning.

How to Structure Alternative Technology Assessment

The structure should follow a logical progression from clinical need to technological options to selection rationale.

Start by clearly defining the clinical problem or need. What condition are you treating? What function are you restoring? What diagnostic information are you providing? Be specific.

Then identify the different classes of technology that address this need. Group by technological principle, not by manufacturer or brand. For a hip implant, you might have cemented versus cementless fixation, different bearing surface materials, different stem geometries based on fixation philosophy.

For each alternative technology class, describe the principle briefly and identify the main clinical advantages and limitations based on published evidence. You are not doing a full literature review here, but you are showing you understand the trade-offs.

Finally, explain why your device uses its particular technological approach. What clinical benefits does it provide? What limitations does it accept? How does this fit the intended use and target population?

The Level of Detail Required

This is where manufacturers often struggle. How much detail is enough?

The answer depends on how different your technology is from established approaches and how much the technological choice impacts the clinical benefit-risk profile.

If you are using a well-established technology with minor modifications, a brief discussion may suffice. If you are introducing a novel approach or combining technologies in new ways, you need more depth.

I worked on a file for a Class III cardiovascular device that used a novel polymer coating. The alternative technology section needed to cover metallic versus polymer materials, different types of polymers, different surface treatment approaches, and the rationale for the specific polymer selected. It ran several pages with over twenty references.

Another file for a Class IIa surgical instrument with standard materials needed only two paragraphs describing alternative instrument designs and why the ergonomic approach was chosen.

The key is proportionality to risk and novelty.

Common Mistakes That Trigger Deficiencies

Beyond confusing products with technologies, several patterns consistently cause problems.

One is ignoring non-device alternatives. If your device treats a condition that could also be managed with drugs or surgery, those alternatives deserve mention. You are not required to do a full comparative effectiveness analysis, but you should acknowledge they exist and explain where your device fits in the treatment pathway.

Another is failing to address why you rejected certain technological approaches. If three main technologies exist and you chose one, what about the other two? Silence suggests you did not consider them, which raises questions about your design and development process.

A third mistake is using only marketing materials or product brochures as sources. Alternative technology assessment should be based on clinical evidence and scientific literature, not commercial claims. If you cite a competitor’s instructions for use, make sure you also cite clinical studies supporting or questioning that approach.

The Equivalence Connection

Here is something many manufacturers miss: your alternative technology assessment directly impacts your ability to claim equivalence.

If you want to demonstrate equivalence to another device under MDR Annex XIV Section 3, you must show that both devices use the same technical principles to achieve the same clinical effect. But how can you argue “same technical principles” if you have not properly analyzed what different technical principles exist?

I have seen equivalence claims collapse because the alternative technology section revealed that the predicate device actually used a fundamentally different approach. The manufacturer had assumed equivalence without analyzing the technology landscape.

A solid alternative technology assessment protects your equivalence strategy by forcing you to clearly define what makes your technology the same or different from others.

Practical Approach for Your Next SOTA

When you sit down to write this section, start by asking: what are the fundamentally different ways to solve this clinical problem?

Look beyond your industry bubble. Search the broader medical and scientific literature, not just regulatory databases. A good alternative technology assessment often references research papers, systematic reviews, and clinical guidelines, not just other technical files.

Create a simple table or diagram showing the technology classes, their principles, main advantages, main limitations, and key clinical evidence. This helps you organize your thinking and makes the section easier for reviewers to assess.

Then write the narrative that connects this landscape to your device. Explain your position in the landscape. Justify your technological choices based on the clinical evidence you identified.

Remember that this section will be read alongside your benefit-risk analysis and your clinical data. Consistency matters. If you claim your technology is superior in some aspect, your clinical evidence section should support that claim.

How This Evolves Over Time

Alternative technology assessment is not static. The state of the art changes. New technologies emerge. Clinical evidence accumulates.

Your initial SOTA may have identified three main approaches. Five years later, there might be six approaches, and the clinical evidence for each has evolved. Your PMCF activities should monitor these changes.

When you update your clinical evaluation, revisit the alternative technology section. Have new approaches appeared? Has the evidence shifted the risk-benefit balance for certain technologies? Does your device still represent an appropriate choice given the current state of the art?

This is particularly important for legacy devices. A technology that was state of the art in 2015 may no longer be optimal in 2025. If you cannot justify why you are still using it, you have a regulatory problem.

What Reviewers Look For

After years of preparing files and responding to Notified Body questions, I can tell you what makes a reviewer satisfied with an alternative technology section.

They want to see that you genuinely understand the field. That you have looked beyond your own product. That you can articulate why different approaches exist and what trade-offs they involve.

They want to see clinical thinking, not marketing thinking. What matters clinically about these technological differences? How do they affect patient outcomes, safety, or usability?

They want to see that your technological choice is deliberate and defensible. You may not have chosen the “best” technology in every dimension, but you can explain why your choice is appropriate for your intended use and target population.

When these elements are present, the alternative technology section becomes a strength in your file. It demonstrates competence and thoroughness. It supports your benefit-risk determination. It reduces questions during assessment.

When these elements are missing, every other claim in your clinical evaluation becomes suspect. If you do not understand the technology landscape, how can your benefit-risk analysis be trusted? If you cannot justify your technological approach, how can your device be considered state of the art?

Moving Forward

If you are preparing a SOTA section now, take thirty minutes to review your alternative technology assessment critically. Are you describing technologies or just listing products? Are you analyzing principles or just comparing features?

If your section feels like it could have been written by your sales team, you probably need to rework it. The voice should be clinical and analytical, not commercial.

If you are reviewing someone else’s work, look for the same things a Notified Body reviewer looks for. Do they demonstrate genuine understanding of the field? Can they justify their technological approach? Is their analysis based on clinical evidence?

This section is more important than most manufacturers realize. It sits at the intersection of your design decisions, your clinical evidence, and your benefit-risk determination. Get it right, and it strengthens your entire technical file. Get it wrong, and it creates doubt about everything else.

The manufacturers who do this well are the ones who think like clinicians, not just device engineers. They understand that choosing a technology means accepting certain clinical trade-offs. They can articulate those trade-offs clearly. They know where their device fits in the broader landscape of solutions.

That understanding cannot be faked. But it can be developed through careful analysis and genuine engagement with the clinical literature. And once you have it, your clinical evaluation becomes much stronger.

Peace,
Hatem
Clinical Evaluation Expert for Medical Devices
Follow me for more insights and practical advice.